Zeitschriftenartikel zum Thema „FK-506 (Drug)“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "FK-506 (Drug)" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Shaw, L. M., und K. L. Brayman. „FK-506 therapeutic drug monitoring“. Clinical Chemistry 40, Nr. 12 (01.12.1994): 2207–8. http://dx.doi.org/10.1093/clinchem/40.12.2207.
Winkler, M., B. Ringe, J. Baumann, M. Loss, K. Wonigeit und R. Pichlmayr. „Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression“. Clinical Chemistry 40, Nr. 12 (01.12.1994): 2247–53. http://dx.doi.org/10.1093/clinchem/40.12.2247.
Dumont, F. J., M. J. Staruch, S. L. Koprak, J. J. Siekierka, C. S. Lin, R. Harrison, T. Sewell, V. M. Kindt, T. R. Beattie und M. Wyvratt. „The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.“ Journal of Experimental Medicine 176, Nr. 3 (01.09.1992): 751–60. http://dx.doi.org/10.1084/jem.176.3.751.
Rokaw, M. D., M. E. West, P. M. Palevsky und J. P. Johnson. „FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells“. American Journal of Physiology-Cell Physiology 271, Nr. 1 (01.07.1996): C194—C202. http://dx.doi.org/10.1152/ajpcell.1996.271.1.c194.
Di Padova, F. E. „Pharmacology of CsA and FK-506“. Perspectives in Drug Discovery and Design 2, Nr. 1 (August 1994): 49–56. http://dx.doi.org/10.1007/bf02171736.
Goulet, Mark T., Kathleen M. Rupprecht, Peter J. Sinclair, Matthew J. Wyvratt und William H. Parsons. „The medicinal chemistry of FK-506“. Perspectives in Drug Discovery and Design 2, Nr. 1 (August 1994): 145–62. http://dx.doi.org/10.1007/bf02171741.
Petros, Andrew M., Gerd Gemmecker, Placido Neri, Edward T. Olejniczak, David Nettesheim, Robert X. Xu, Earl G. Gubbins, Harriet Smith und Stephen W. Fesik. „NMR studies of an FK-506 analog, [U-carbon-13]ascomycin, bound to FK-506-binding protein“. Journal of Medicinal Chemistry 35, Nr. 13 (Juni 1992): 2467–73. http://dx.doi.org/10.1021/jm00091a015.
Kay, John E., Senam E. A. Doe und C. Robin Benzie. „The mechanism of action of the immunosuppressive drug FK-506“. Cellular Immunology 124, Nr. 1 (November 1989): 175–81. http://dx.doi.org/10.1016/0008-8749(89)90121-4.
O'connor, Stephen P., Robert L. Ellsworth, Mary Nallin Omstead, Rosalind G. Jenkins und Louis Kaplan. „The preparation of 14C-labeled FK-506“. Journal of Labelled Compounds and Radiopharmaceuticals 31, Nr. 2 (Februar 1992): 103–8. http://dx.doi.org/10.1002/jlcr.2580310205.
Jusko, William J. „Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug Monitoring“. Therapeutic Drug Monitoring 17, Nr. 6 (Dezember 1995): 596–601. http://dx.doi.org/10.1097/00007691-199512000-00009.
Clardy, Jon. „Structural studies on FK-506, cyclosporin A and their immunophilin complexes“. Perspectives in Drug Discovery and Design 2, Nr. 1 (August 1994): 127–44. http://dx.doi.org/10.1007/bf02171740.
DOE, SENAM E. A., C. ROBIN BENZIE und JOHN E. KAY. „Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes“. Biochemical Society Transactions 18, Nr. 3 (01.06.1990): 451–52. http://dx.doi.org/10.1042/bst0180451.
Takabayashi, Katsuhiko, Takao Koike, Kazuhiro Kurasawa, Ryutaro Matsumura, Toshiko Sato, Hisao Tomioka, Isao Ito, Takashi Yoshiki und Sho Yoshida. „Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus“. Clinical Immunology and Immunopathology 51, Nr. 1 (April 1989): 110–17. http://dx.doi.org/10.1016/0090-1229(89)90211-0.
Patel, S. S., M. S. Patel, S. Salampure, B. Vishwanath und N. M. Patel. „Development and Evaluation of Liposomes for Topical Delivery of Tacrolimus (Fk-506)“. Journal of Scientific Research 2, Nr. 3 (24.08.2010): 585. http://dx.doi.org/10.3329/jsr.v2i3.3258.
Shitrit, David, Jacob E. Ollech, Ayelet Ollech, Ilana Bakal, Milton Saute, Gideon Sahar und Mordechai R. Kramer. „Itraconazole Prophylaxis in Lung Transplant Recipients Receiving Tacrolimus (FK 506): Efficacy and Drug Interaction“. Journal of Heart and Lung Transplantation 24, Nr. 12 (Dezember 2005): 2148–52. http://dx.doi.org/10.1016/j.healun.2005.05.003.
Acemoglu, Murat, Hendrik Andres und Thomas Moenius. „Regio- and stereoselective preparation of ascomycin-d1 and FK 506-d1“. Journal of Labelled Compounds and Radiopharmaceuticals 45, Nr. 5 (2002): 361–70. http://dx.doi.org/10.1002/jlcr.558.
Kramer, Mordechai R., Anat Amital, Leonardo Fuks und David Shitrit. „Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction“. Clinical Transplantation 25, Nr. 2 (16.12.2010): E163—E167. http://dx.doi.org/10.1111/j.1399-0012.2010.01373.x.
O'Keefe, Stephen J., und Edward A. O'Neill. „Cyclosporin A and FK-506: Immunosuppression, inhibition of transcription and the role of calcineurin“. Perspectives in Drug Discovery and Design 2, Nr. 1 (August 1994): 85–102. http://dx.doi.org/10.1007/bf02171738.
White, James D., Jörg Deerberg, Steven G. Toske und Takayuki Yakura. „Application of stereocontrolled aldol coupling to synthesis of segments of immunosuppressants FK-506 and rapamycin“. Tetrahedron 65, Nr. 33 (August 2009): 6635–41. http://dx.doi.org/10.1016/j.tet.2009.06.030.
Oyouni, AtifAbdulwahab A., Shalini Saggu, Ehab Tousson, Anand Mohan und Abdullah Farasani. „Mitochondrial nephrotoxicity induced by tacrolimus (FK-506) and modulatory effects of Bacopa monnieri (Farafakh) of Tabuk Region“. Pharmacognosy Research 11, Nr. 1 (2019): 20. http://dx.doi.org/10.4103/pr.pr_100_18.
Schnider, Jonas T., Matthias Weinstock, Jan A. Plock, Mario G. Solari, Raman Venkataramanan, Xin Xiao Zheng und Vijay S. Gorantla. „Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential“. Clinical and Developmental Immunology 2013 (2013): 1–7. http://dx.doi.org/10.1155/2013/495212.
Kay, John E., und C. Robin Benzie. „T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506“. Immunology Letters 23, Nr. 2 (Dezember 1989): 155–59. http://dx.doi.org/10.1016/0165-2478(89)90129-6.
Shevchenko, V. P., I. Yu Nagaev, N. F. Myasoedov, H. Andres, T. Moenius und A. Susan. „Synthesis of tritiated Cyclosporin A and FK-506 by metal-catalyzed hydrogen isotope exchange“. Journal of Labelled Compounds and Radiopharmaceuticals 47, Nr. 7 (Juni 2004): 407–14. http://dx.doi.org/10.1002/jlcr.827.
Chung, Shu-Ying, Fu-Chou Cheng, Ming-Shih Lee, Jing-Ying Lin, Ming-Cheng Lin und Ming-Fu Wang. „Ginkgo biloba Leaf Extract (EGb761) Combined with Neuroprotective Agents Reduces the Infarct Volumes of Gerbil Ischemic Brain“. American Journal of Chinese Medicine 34, Nr. 05 (Januar 2006): 803–17. http://dx.doi.org/10.1142/s0192415x06004302.
Wong, S. H. Y., B. Ghodgaonkar, P. Fong, B. Campbell, J. F. Burdick und F. Boctor. „Supercritical Fluid Chromatography for Therapeutic Drug Monitoring of Immunosuppressants: Selectivity for Cyclosporine A, Fk 506 (Tacrolimus), and Rapamycin“. Journal of Liquid Chromatography 17, Nr. 10 (Juni 1994): 2093–109. http://dx.doi.org/10.1080/10826079408013534.
Lhoest, G., N. Maton, A. Laurent und R. K. Verbeeck. „Isolation and identification of a FK-506 C36–C37 dihydrodiol from erythromycin-induced rabbit liver microsomes“. Journal of Pharmaceutical and Biomedical Analysis 12, Nr. 2 (Februar 1994): 235–41. http://dx.doi.org/10.1016/0731-7085(94)90034-5.
Yu, JS, S. Lee, HJ Eom, HR Kang, SR Lee, TK Lee, J. Baek et al. „Protective effect of Korean red ginseng against FK-506-induced damage in LLC-PK1 cells“. Planta Medica 81, S 01 (14.12.2016): S1—S381. http://dx.doi.org/10.1055/s-0036-1596887.
Cryan, John, Shirley H. Y. Hung, Gregory Wiederrecht, Nolan H. Sigal und John J. Siekierka. „FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity“. Biochemical and Biophysical Research Communications 180, Nr. 2 (Oktober 1991): 846–52. http://dx.doi.org/10.1016/s0006-291x(05)81142-8.
Petros, A. M., R. T. Gampe, G. Gemmecker, P. Neri, T. F. Holzman, R. Edalji, J. Hochlowski, M. Jackson und J. McAlpine. „NMR studies of an FK-506 analog [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding“. Journal of Medicinal Chemistry 34, Nr. 9 (September 1991): 2925–28. http://dx.doi.org/10.1021/jm00113a037.
Banholzer, R., A. P. Nair, H. H. Hirsch, X. F. Ming und C. Moroni. „Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3' untranslated region.“ Molecular and Cellular Biology 17, Nr. 6 (Juni 1997): 3254–60. http://dx.doi.org/10.1128/mcb.17.6.3254.
Bansal, Puneet, und Anil Kumar. „P1-194: Novel drug strategies and molecular mechanisms of lycopene, FK-506 and venlafaxine against 3-NP induced Huntington's-like symptoms in rats“. Alzheimer's & Dementia 8, Nr. 4S_Part_5 (Juli 2012): P174—P175. http://dx.doi.org/10.1016/j.jalz.2012.05.472.
Tran, Quang Hieu Dé, Elizabeth Guay, Suzanne Chartier und Jacqueline Tousignant. „Tacrolimus in Dermatology“. Journal of Cutaneous Medicine and Surgery 5, Nr. 4 (Juli 2001): 329–35. http://dx.doi.org/10.1177/120347540100500409.
Furue, Masutaka, Atsushi Osada und Kunihiko Tamaki. „Inhibition of contact hypersensitivity by an anti-allergic drug, azelastine, is likely to be mediated by its novel immunosuppressive effects distinct from FK-506“. Journal of Dermatological Science 6, Nr. 1 (August 1993): 75. http://dx.doi.org/10.1016/0923-1811(93)91148-n.
WOO, J., C. S. K. ROSS, J. I. MILTON und A. W. THOMSON. „Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal“. Clinical & Experimental Immunology 79, Nr. 1 (28.06.2008): 109–14. http://dx.doi.org/10.1111/j.1365-2249.1990.tb05136.x.
Vannucchi, AM, A. Grossi, A. Bosi, D. Rafanelli, M. Statello, S. Guidi, R. Saccardi und P. Rossi-Ferrini. „Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line“. Blood 82, Nr. 3 (01.08.1993): 978–84. http://dx.doi.org/10.1182/blood.v82.3.978.978.
Vannucchi, AM, A. Grossi, A. Bosi, D. Rafanelli, M. Statello, S. Guidi, R. Saccardi und P. Rossi-Ferrini. „Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line“. Blood 82, Nr. 3 (01.08.1993): 978–84. http://dx.doi.org/10.1182/blood.v82.3.978.bloodjournal823978.
KASS, LEONARD, DORETTE Z. ELLIS, JANICE PELLETIER, NATHAN E. TABLEMAN und SAMUEL C. EDWARDS. „Inhibition of the calcineurin-like protein phosphatase activity in Limulus ventral eye photoreceptor cells alters the characteristics of the spontaneous quantal bumps and the light-mediated inward currents, and enhances arrestin phosphorylation“. Visual Neuroscience 15, Nr. 6 (November 1998): 1039–49. http://dx.doi.org/10.1017/s0952523898156031.
Lopatynska-Mazurek, Malgorzata, Lukasz Komsta, Ewa Gibula-Tarlowska und Jolanta H. Kotlinska. „Aversive Learning Deficits and Depressive-Like Behaviors Are Accompanied by an Increase in Oxidative Stress in a Rat Model of Fetal Alcohol Spectrum Disorders: The Protective Effect of Rapamycin“. International Journal of Molecular Sciences 22, Nr. 13 (30.06.2021): 7083. http://dx.doi.org/10.3390/ijms22137083.
Lemster, B., L. L. Huang, W. Irish, J. Woo, P. B. Carroll, K. Abu-Elmagd, H. R. Rilo et al. „Influence of FK 506 (Tacrolimus) On Circulating CD4+T Cells Expressing Cd25 and Cd45ra Antigens in 19 Patients with Chronic Progressive Multiple Sclerosis Participating in an Open Label Drug Safety Trial“. Autoimmunity 19, Nr. 2 (Januar 1994): 89–98. http://dx.doi.org/10.3109/08916939409009536.
Chow, Kai Uwe, Daniel Nowak, Soo-Zin Kim, Bernd Schneider, Martina Komor, Simone Boehrer, Paris S. Mitrou, Dieter Hoelzer, Eckhart Weidmann und Wolf-Karsten Hofmann. „In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin’s Lymphomas Is Predicted by In Vitro Chemosensitivity Testing and Gene Expression Profiling.“ Blood 104, Nr. 11 (16.11.2004): 2273. http://dx.doi.org/10.1182/blood.v104.11.2273.2273.
Yue, Gang, Robert S. Edinger, Hui-Fang Bao, John P. Johnson und Douglas C. Eaton. „The effect of rapamycin on single ENaC channel activity and phosphorylation in A6 cells“. American Journal of Physiology-Cell Physiology 279, Nr. 1 (01.07.2000): C81—C88. http://dx.doi.org/10.1152/ajpcell.2000.279.1.c81.
Edinger, Robert S., Simon C. Watkins, David Pearce und John P. Johnson. „Effect of immunosuppressive agents on glucocorticoid receptor function in A6 cells“. American Journal of Physiology-Renal Physiology 283, Nr. 2 (01.08.2002): F254—F261. http://dx.doi.org/10.1152/ajprenal.00337.2001.
Tumlin, J. A., J. T. Someren, C. E. Swanson und J. P. Lea. „Expression of calcineurin activity and alpha-subunit isoforms in specific segments of the rat nephron“. American Journal of Physiology-Renal Physiology 269, Nr. 4 (01.10.1995): F558—F563. http://dx.doi.org/10.1152/ajprenal.1995.269.4.f558.
Dušková, M., L. Dušek, M. Čìž, A. Lojek und H. Slavíková. „The Influence of Some Immunosuppressive Drugs on the Metabolic Activity of Human Phagocytes and Lymphocytes in vitro“. International Journal of Immunopathology and Pharmacology 11, Nr. 3 (September 1998): 155–62. http://dx.doi.org/10.1177/039463209801100305.
Hodge, Shekema, Juliette de Rosayro, Amanda Glenn, Ifeoma C. Ojukwu, Stephen Dewhurst, Harold M. McClure, Norbert Bischofberger, Daniel C. Anderson, Sherry A. Klumpp und Francis J. Novembre. „Postinoculation PMPA Treatment, but Not Preinoculation Immunomodulatory Therapy, Protects against Development of Acute Disease Induced by the Unique Simian Immunodeficiency Virus SIVsmmPBj“. Journal of Virology 73, Nr. 10 (01.10.1999): 8630–39. http://dx.doi.org/10.1128/jvi.73.10.8630-8639.1999.
Siekierka, John J. „Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin“. Immunologic Research 13, Nr. 2-3 (Juni 1994): 110–16. http://dx.doi.org/10.1007/bf02918272.
Poolos, Nicholas P. „Hypoxia Results in GABAergic Channelopathy“. Epilepsy Currents 5, Nr. 6 (November 2005): 234–35. http://dx.doi.org/10.1111/j.1535-7511.2005.00073.x.
Esteves, Iracema, Juliana F. Fernandes, Andreza Feitosa Ribeiro, Fabio P. S. Santos, Ricardo Helman, Claudio Castro Junior, Vinicius R. P. Mattos et al. „The Clinical and Therapeutic Drug Monitoring of Oral and Intravenous Busulfan in Patients with Acute Leukemia That Underwent to Stem Cell Transplantation with a Test Dose of Busulfan“. Blood 124, Nr. 21 (06.12.2014): 5841. http://dx.doi.org/10.1182/blood.v124.21.5841.5841.
Li, Dailin, Sam Xian Jun Cheng, Gilberto Fisone, Michael J. Caplan, Yoshiyuki Ohtomo und Anita Aperia. „Effects of okadaic acid, calyculin A, and PDBu on state of phosphorylation of rat renal Na+-K+-ATPase“. American Journal of Physiology-Renal Physiology 275, Nr. 6 (01.12.1998): F863—F869. http://dx.doi.org/10.1152/ajprenal.1998.275.6.f863.
Karpas, A., M. Lowdell, S. K. Jacobson und F. Hill. „Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506.“ Proceedings of the National Academy of Sciences 89, Nr. 17 (01.09.1992): 8351–55. http://dx.doi.org/10.1073/pnas.89.17.8351.